Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study is a pilot randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin in adult outpatients suspected to be afflicted with COVID-19.
Description: Evaluate the incidence of serious adverse effects and discontinuation secondary to toxicity through 28 days of follow-up as compared to the control arm as assessed by: Cumulative incidence of serious adverse events (SAEs), Cumulative incidence of Grade 3 and 4 adverse events (AEs), Discontinuation or temporary suspension of the investigational medication (for any reason).
Measure: Cumulative Incidence of Treatment-Emergent Adverse Events Time: 28 daysDescription: Incidence of COVID-19 related hospitalization at 28 days
Measure: Hospitalization Time: 28 daysDescription: COVID-19 related symptoms (Fever, chills, cough, nasal symptoms, body aches/muscle aches, headache, loss of smell, loss of taste, nausea, vomiting, diarrhea, fatigue, dizziness) that are self-reported and on interview.
Measure: COVID-19 related symptoms Time: 28 daysDescription: Change from baseline (day 1) as assessed to days 3, 7, 14, and 28
Measure: Rate of resolution of COVID-19 related symptoms Time: 28 daysDescription: 28-day mortality
Measure: Mortality Time: 28 days